{
    "nctId": "NCT01246973",
    "briefTitle": "Oral Curcumin for Radiation Dermatitis",
    "officialTitle": "Oral Curcumin for Radiation Dermatitis in Breast Cancer Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Radiation-induced Dermatitis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 686,
    "primaryOutcomeMeasure": "Mean Radiation Dermatitis Severity Score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* a diagnosis of non-inflammatory breast adenocarcinoma (including in situ and bilateral)\n* scheduled to begin radiotherapy without concurrent chemotherapy; concurrent hormone or Herceptin\u00ae (trastuzumab)treatment is okay\n* can have been treated by lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment\n* can have had breast reconstruction\n* scheduled to receive 25-35 radiation treatment sessions (1 session per day) using standard irradiation fractionation (1.8-2.0 Gy per sessions) OR 16-20 radiation treatment sessions (1 session per day) using Canadian irradiation fractionation (2.2-3.0 Gy per session)(100, 101).\n* able to swallow medication.\n* three weeks must have elapsed after chemotherapy and surgery before the patient can begin the study\n* able to understand English\n\nExclusion Criteria:\n\n* inflammatory breast cancer\n* previous radiation therapy to the breast or chest\n* concurrent chemotherapy treatment\n* concurrent treatment with anti-coagulants (e.g., coumadin\u00ae, warfarin\u00ae), or anti-EGFR (human epidermal growth factor receptor) drugs (e.g. Iressa\u00ae (gefitinib), Erbitux\u00ae (cetuximab, C225); aspirin is allowed\n* known radiosensitivity syndromes (e.g., Ataxia-telangiectasia)\n* collagen vascular disease, unhealed surgical sites, or breast infections",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}